RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DIECI MV
Collezione AO Cuneo

Items : 4

Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;154:21-29. doi: 10.1016/j.ejca.2021.05.008. Epub 2021 Jul 2.

2021
AO Cuneo

Guarneri V; Giorgi CA; Cinieri S; Bengala C; Mariani G; Bisagni G; Frassoldati A; Zamagni C; De Rossi C; Amoroso V; Andreetta C; Ferro A; Zambelli A; Gori S; Garrone O; Dieci MV; Orlando L; Pastina I; Beninato T; Moretti G; Genovesi E; Cinefra M; Vicini R; Magni G; De Salvo GL; Conte P; Guarneri V; Giorgi CA; Cinieri S; et alii...

PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2(+) Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2020 Nov 15;26(22):5843-5851. doi: 10.1158/1078-0432.CCR-20-1731. Epub 2020 Aug 25.

2020
AO Cuneo

Urso L; Paré L; Curtarello M; Griguolo G; Orvieto E; Piacentini F; Nanni O; Cagossi K; Bertone E; Garrone O; Rimanti A; Giotta F; Musolino A; Frassoldati A; Cavanna L; Brandes AA; Bisagni G; Dieci MV; Guarneri V; Chic N; D'Amico R; Prat A; Conte P;

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. in BMC medicine / BMC Med. 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z.

2019
AO Cuneo
AOU Città della Salute di Torino

Conte PF; Guarneri V; Griguolo G; D'Amico R; Vicini R; Balduzzi S; Foschini MP; Moretti G; Amaducci L; Bazan V; Romito S; Gambaro AR; Sarti S; Ferro A; Cagossi K; Danese S; Piacentini F; Soto Parra H; Zamagni C; Beano A; Rimanti A; Donadio M; Garrone O; Musolino A; Gebbia V; Aieta M; Giotta F; Cavanna L; Frassoldati A; et alii...

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Mar 1;30(3):418-423. doi: 10.1093/annonc/mdz007.

2019
AO Cuneo

Miglietta F; Orvieto E; Sanders M; Maiorana A; Piacentini F; Ferro A; Sarti S; Cagossi K; Bertone E; Garrone O; Rimanti A; Giotta F; Cavanna L; Musolino A; Frassoldati A; Brandes AA; Bisagni G; Conte P; Dieci MV; Balduzzi S; D'Amico R; Guarneri V;